Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Hold” from Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received an average recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th.

Insider Buying and Selling

In other Xeris Biopharma news, Director James Aloysius Brady sold 10,834 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $5.54, for a total transaction of $60,020.36. Following the sale, the director directly owned 89,166 shares in the company, valued at $493,979.64. This represents a 10.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider owned 1,193,173 shares in the company, valued at approximately $7,433,467.79. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 60,835 shares of company stock worth $367,860. Company insiders own 6.47% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of XERS. Kestra Advisory Services LLC purchased a new stake in shares of Xeris Biopharma in the fourth quarter worth approximately $25,000. KBC Group NV purchased a new stake in shares of Xeris Biopharma in the first quarter worth approximately $27,000. AlphaQuest LLC purchased a new stake in shares of Xeris Biopharma in the third quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $6.19 on Tuesday. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The company has a market capitalization of $1.07 billion, a P/E ratio of 103.17 and a beta of 0.85. Xeris Biopharma has a 12 month low of $4.30 and a 12 month high of $10.08. The business’s 50-day moving average is $5.98 and its 200 day moving average is $6.69.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. On average, equities research analysts forecast that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.